Glen Eagle Advisors, LLC Roivant Sciences Ltd. Transaction History
Glen Eagle Advisors, LLC
- $603 Billion
- Q4 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 435 shares of ROIV stock, worth $4,367. This represents 0.0% of its overall portfolio holdings.
Number of Shares
435
Previous 435
-0.0%
Holding current value
$4,367
Previous $5.02 Million
2.51%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
328Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$661 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$623 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$480 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$443 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$355 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.07B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...